Cheap Cialis Blogger | Search results for "practice"

"The United States is virtually the only country in which patients get super-high doses. You create a toxicity situation," said Dr. N.D. Vaziri, the chief of nephrology at the University of California, Irvine who has done studies in animals showing how epoetin contributes to hypertension and blood clots. Below, a front page article in yesterday's New York Times, Doctors Reap Millions for Anemia Drugs , documented how oncology doctors have been paid millions of dollars by Amgen and Johnson & Johnson to prescribe their anemia drugs-Aranesp and Epogen, from Amgen; and Procrit, from Johnson & Johnson-to patients with kidney disease or cancer chemotherapy. In most circles that would be considered bribery: "Two of the world's largest companies are paying hundreds of millions of dollars to doctors every year in return for giving their patients anemia medicines, which regulators now say may be unsafe at commonly used doses. The payments are legal, but very few people outside of the doctors who receive them are aware of their size." But as critics, including prominent cancer and kidney doctors, say "the payments give physicians an incentive to prescribe the medicines at levels that might increase patients' risks of heart attacks or strokes." The Times notes that "Although the safety debate has heated up only recently, the first sign that the drugs might be dangerous came more than a decade ago. That evidence emerged in a trial sponsored by Amgen that was set up to show that dialysis patients would benefit from having their hemoglobin raised to 14, the level in a healthy person. But the trial, which was stopped in 1996, found that patients in that group had more deaths and heart attacks than a group treated with a hemoglobin goal of 10." "That trial should have discouraged doctors from using too much epoetin and encouraged Amgen to study the risks further, said Dr. Steven Fishbane, a nephrologist at Winthrop-University Hospital on Long Island. Instead, use of epoetin continued to soar." Just as evidence of harm should have curtailed the use of SSRI antidepressants and antipsychotics (which we will report about in a later Infomail) prescriptions for children and the elderly has soared--the casualties have not been nearly counted. "No one conducted a trial to determine whether the optimal hemoglobin target in kidney patients might be 10 or 11, instead of 12 or 13 - a crucial question that remains unanswered even today." [Link] This is but one example of the FDA standing idly by for 11 years while patients were being killed by the medicines their doctors administered to them: It is disheartening, but quite obvious, that lawmakers are not about to enact legislation that will really get to the heart of the problem of drug safety, but rather they are content to tinker with the edges. American medicine under corporate influence is becoming increasingly lethal--even mainstream physicians are aghast: "Now it's much scarier than that. We could really be doing harm." Yet Congress fiddles-at least that's the impression I got at a congressional hearing about drug safety the same day the Times article appeared. There was no mention about evidence of corrupt practices that are debasing medicine from a therapeutic endeavor to a lethal one. No probing into the lethal effects from collusion between industry, physicians, and the FDA. Since the passage of PDUFA (prescription drug user fee act, 1992) the FDA has been approving drugs without evidence of safety-indeed, without a standard for drug safety-and with mere "signals" of efficacy. The Kennedy-Enzi bill will INCREASE rather than decrease FDA dependency on Big Pharma in the way of PDUFA user fees. Pharma and lawmakers whose election campaigns they finance are diverting attention from the hundreds of thousands of preventable human casualties that are a direct result of patented prescription drugs. Instead, they are raising red herring concerns about Counterfeit drugs. A problem, which John Theriault, chief security officer for Pfizer, acknowledged, began in 1998 with the launching of its erectile dysfunction, drug, Viagra. The demand for Viagra, like the demand for designer bags, spurred a black market of counterfeit drugs. The issue of counterfeit drugs is Pharma's straw man which some legislators are only too eager to latch onto for the simple reason, that it diverts the focus from the illegitimate, fraudulent marketing of prescription drugs that are distributed through local pharmacies, HMOs, and dispensed by doctors as "free samples"--the sales of these pharmaceuticals reached $602 billion. [1] These tainted drugs carry the FDA seal of approval, are prescribed by U.S. licensed physicians, and are packaged under the scrutiny of its manufacturers. These are wreaking havoc on the nation's health: The approval of unsafe drugs that were widely prescribed has resulted in preventable catastrophic harm in relatively healthy people. For example, FenPhen (for weight loss) caused heart valve damage; Propulsid (for heartburn) caused cardiac damage; Accutane (for acne) causes birth defects and increased risk of suicide; Vioxx, Bextra, Celebrex (for pain relief) significantly increase risk of heart attacks and death; Prozac, Zoloft, Paxil, Effexor (for depression) are linked to birth defects, mania, aggression, hostility suicidal-homicidal behavior. Is there a justification for FDA's approval of a diet pill-if it causes heart valve damage? Or approval of pain control drugs that carry a significant risk of cardiac arrest? Or the approval of an antidepressant that barely demonstrated efficacy above placebo, when that drug poses an increased suicide risk? Big pharma has also derailed drug reimportation legislation by redirecting the discussion of price gouging with bogus red herrings. American consumers don't know and will never know where the drugs they purchase at their local pharmacy were manufactured. Mostly NOT in the U.S. Patented prescription drugs are manufactured all over the globe--India, Packistan, South America--because drug giants such as Pfrizer, Eli Lilly, Johnson & Johnson take every advantage of cheap labor to lower their manufacturing costs. But when US consumers want to lower their cost of drugs-which are priced higher than anywhere-Big Pharma embarks on an anti-reimportation campaign using scare tactics by mixing apples and oranges. Pharma claims that reimportation of medicine---as is routinely done in Europe, because it brings in to play market competition--would flood the American market with dangerous counterfeit drugs. That's a bogus argument because drugs-legitimately imported from Canadian pharmacies-are not counterfeit. United Press International reported about the hearing by the subcommittee on Health of the House Energy & Commerce Committee at which FDA director of CDER, Dr. Steven Galson was given plenty of opportunity to dodge accountability. Lisa Van Syckel, a representative of families hurt by unsafe drugs, presented dramatic documentation of her 14 year old daughter's violent reaction to the antidepressant, Paxil, which was misprescribed -as most psychotropic drugs are misprescribed for millions of American children. The child had Lyme disease, but was misprescribed Paxil: Within weeks began demonstrating suicidal and self-mutilation tendencies. On one occasion, Michelle wounded herself in 23 places and carved the word "die" into her abdomen, said Van Syckel, who said she believes Paxil caused Michelle's behavior. "Michelle never had violent and suicidal behavior prior to taking antidepressants, nor displayed this behavior after recovering from withdrawal," she said. Ms. Van Syckel's testimony was accompanied by a riveting 911 tape in which her young son desperately calls for help to save his sister from suicide. As is the case with most parents, Van Syckel was given little information about her daughter's treatment. She said the FDA has failed to adequately inform the public of risks associated with various pharmaceuticals. Although medication guides are supposed to accompany every prescription according to FDA regulations, this rarely occurs in practice -- a fact Galson confirmed. Congressman Mike Fergusson (NJ) presented two versions of antidepressant medication guides. Dr. Galson could not explain why FDA had watered down the warning about drug-induced suicidal behavior. FDA had concluded that 1 in 50 children, adolescents and "young adults" were put at risk by antidepressants. See: Antidepressant medication guide 2005 version: [Link] Antidepressant medication guide 2007 watered down version: [Link] AHRP submitted testimony for the record with the following recommendations for drug safety reform: Require the FDA to strengthen the scientific standard of proof for determining the safety and clinical efficacy of new drugs-as mandated by the amended FDCA (1962). Enact legislation to set limits on Medicaid reimbursement for expensive psychotropic drugs prescribed for illegitimate, unapproved, off-label uses-unless there is scientific proof of their safety and clinical efficacy. Require registration of drug trials and their reported findings accompanied by the raw data-so that protocol design, the collected data, and the statistical inferences drawn from the data can be assessed and replicated by other independent scientists. Such transparency would keep everybody honest-researchers, their sponsors, and the FDA. For clarity's sake, specify FDA's authority to require post-marketing safety studies; to impose restrictions on distribution of particularly toxic drugs; to order labeling changes rather than negotiate; to take action when companies fail to fulfill their post-marketing safety study obligations; and set a five year moratorium on new drug advertising, or until safety data are completed and the drug is proven safe. Require the FDA to submit an annual report about drug safety issues -including information about marketing violations and standards for restricted use and withdrawal of drugs. Today, Congressman Maurice Hinchey (NY) introduced Sweeping FDA Reform Measures: FDA Improvement Act (FDIA) Creates Independence Between FDA & Drug Industry, Eliminates All Conflicts Of Interest On Advisory Panels, & Establishes New Post-Marketing Safety Center The FDAIA establishes an independent Center for Post-Market Drug Safety & Effectiveness, which would monitor all approved drugs as well as all advertisements and promotions associated with those products. Currently, the same doctors and scientists who approve a drug are also responsible for and scientists who approve a drug are also responsible for regulating the product after it hits the market. Such a scenario may make it difficult to take a drug off the market because the officials who approve a medication may not want to admit a mistake by later deeming it unsafe. Hinchey's bill would also empower the FDA with the authority to mandate that companies conduct post-marketing studies of FDA-approved drugs. Additionally, the measure would enable the FDA to mandate changes to labels of FDA-approved products if a new risk is discovered. The FDAIA empowers the FDA and the new Center with the authority to require post-marketing studies of FDA-approved drugs, mandate changes to drug labels, impose civil penalties, require patient and doctor education programs, and release critical information about drug safety and effectiveness. "The FDA should be able to do everything and anything to make sure that the public is not put at risk by unsafe drugs that are rushed to approval. Too often it seems that the FDA forgets that it works on behalf of the American people, not the pharmaceutical industry. That is a fundamental problem that must be addressed." See: [Link] html References: See, partial list of U.S. Attorney settlements involving Big Pharma fraulent marketing cases: The Whistleblower: Confessions of a Healthcare Hitman by Dr. Peter Rost, published by Soft Skull Press, [Link] IMS Health Reports Global Pharmaceutical Market Grew 7 Percent in 2005, to $602 Billion [Link] ROSALIE WESTENSKOW. ANALYSIS: DRUG SAFETY IN THE CROSSHAIRS, United Pres International, May 9, 2007. [Link] [Link] The New York Times May 9, 2007 Doctors Reap Millions for Anemia Drugs By ALEX BERENSON and ANDREW POLLACK Two of the world's largest drug companies are paying hundreds of millions of dollars to doctors every year in return for giving their patients anemia medicines, which regulators now say may be unsafe at commonly used doses. The payments are legal, but very few people outside of the doctors who receive them are aware of their size. Critics, including prominent cancer and kidney doctors, say the payments give physicians an incentive to prescribe the medicines at levels that might increase patients' risks of heart attacks or strokes. Industry analysts estimate that such payments - to cancer doctors and the other big users of the drugs, kidney dialysis centers - total hundreds of millions of dollars a year and are an important source of profit for doctors and the centers. The payments have risen over the last several years, as the makers of the drugs, Amgen and Johnson & Johnson, compete for market share and try to expand the overall business. Neither Amgen nor Johnson & Johnson has disclosed the total amount of the payments. But documents given to The New York Times show that at just one practice in the Pacific Northwest, a group of six cancer doctors received $2.7 million from Amgen for prescribing $9 million worth of its drugs last year. Yesterday, the Food and Drug Administration added to concerns about the drugs, releasing a report that suggested that their use might need to be curtailed in cancer patients. The report, prepared by F.D.A. staff scientists, said no evidence indicated that the medicines either improved quality of life in patients or extended their survival, while several studies suggested that the drugs can shorten patients' lives when used at high doses. Yesterday's report followed the F.D.A.'s decision in March to strengthen warnings on the drugs' labels. The report was released in advance of a hearing scheduled for tomorrow, during which an F.D.A. advisory panel will consider whether the drugs are overused. The medicines - Aranesp and Epogen, from Amgen; and Procrit, from Johnson & Johnson - are among the world's top-selling drugs, with combined sales of $10 billion last year. In this country, they represent the single biggest drug expense for Medicare and are given to about a million patients each year to treat anemia caused by kidney disease or cancer chemotherapy. Dr. Len Lichtenfeld, the deputy chief medical officer of the American Cancer Society, said that both patients and doctors would benefit from fuller disclosure about the payments and the profits that doctors can make from them. "I suspect that Medicare is going to take a very careful look at what is going on here," he said. Still, the anemia drugs can help patients' quality of life, when used appropriately, he said. "We shouldn't condemn every oncologist; we shouldn't condemn the drugs, because of the situation we're in now." Federal laws bar drug companies from paying doctors to prescribe medicines that are given in pill form and purchased by patients from pharmacies. But companies can rebate part of the price that doctors pay for drugs, like the anemia medicines, which they dispense in their offices as part of treatment. The anemia drugs are injected or given intravenously in physicians' offices or dialysis centers. Doctors receive the rebates after they buy the drugs from the companies. But they also receive reimbursement from Medicare or private insurers for the drugs, often at a markup over the doctors' purchase price. Medicare has changed its payment structure since 2003 to reduce the markup, but private insurers still often pay more. Combined with those insurance reimbursements, the rebates enable many doctors to profit substantially on the medicines they buy and then give to patients. The rebates are related to the amount of drugs that doctors buy, and physicians that agree to use one company's drugs exclusively typically receive higher rebates. Johnson & Johnson said yesterday in a statement that its rebates were not intended to induce doctors to use more medicine. Instead, the rebates "reflect intense competition" in the market for the drugs, the company said. Amgen said that rebates were a normal commercial practice and that it had always properly promoted its drugs. "Amgen is dedicated to patient safety," said David Polk, a spokesman. "We believe our contracts support appropriate anemia management and our product promotion is always strictly within the label." Both companies' stocks fell yesterday after release of the F.D.A. report. Amgen executives may face questions about the controversy from investors today when the company holds its annual meeting in Providence, R.I. Since 1991, when the first of the drugs was still relatively new, the average dose given to dialysis patients in this country has nearly tripled. About 50 percent of dialysis patients now receive enough of the drugs to raise their red blood cell counts above the level considered risky by the F.D.A. American patients receive far more of the anemia drugs than patients elsewhere, with dialysis patients in this country getting doses more than twice as high as their counterparts in Europe. Cancer care shows a similar pattern. American cancer patients are about three times as likely as those in Europe to get the drugs, and they receive somewhat higher doses. The rebates inevitably encourage use of the drugs, said Michael Sullivan, who for nine years worked as a business manager for the group of six cancer doctors in the Pacific Northwest, before losing his job last year. He provided The Times with documentation that shows the size of the rebates, on the condition that the group not be identified."Personally, I think rebates should go away," said Mr. Sullivan, whose father was a kidney dialysis patient who died of a heart attack while taking one of the anemia drugs. "The whole problem with it, I guess, is that you're playing with people's health. It's not the same as buying widgets." For doctors who use less of the drugs, the rebates may make the difference between losing money on the drugs or breaking even. Mr. Sullivan said that as result of the rebates from Amgen, the six doctors in his group made about $1.8 million in net profit on the drugs they prescribed. Unlike most drugs, the anemia medicines do not come in fixed doses. Therefore, doctors have great flexibility to increase dosing - and profits. Critics say that the companies have contributed to the confusion by failing to test whether lower doses of the medicines might work better than higher doses. "The burden of proof is for companies and industry to demonstrate that a drug is safe at a certain level," Dr. Ajay Singh, an associate professor at Harvard Medical School. Dr. Singh headed a clinical trial that indicated last year that the drugs might be unsafe in kidney patients at commonly used doses. Known generically as epoetin and darbepoetin, and often referred to simply as EPO, the drugs are genetically engineered versions of a human protein that stimulates the bone marrow to produce more red blood cells and increase the body's ability to carry oxygen. Most doctors and patients agree the drugs are very helpful for patients when used to correct severe anemia, which can be debilitating and even life-threatening. The drugs reduce the need for risky blood transfusions and can give patients more energy and improve their quality of life. "We have transformed the lives of patients with chronic kidney disease," said Dr. Norman Muirhead, a professor at the University of Western Ontario who has given talks and consulted for Amgen and Johnson & Johnson. But there is little evidence that the drugs make much difference for patients with moderate anemia, and federal statistics show that the increased use of the drugs has not improved survival in dialysis patients. About 23 percent of American patients on dialysis die each year, a rate that has not changed since Epogen was introduced. Anemia is measured by a patient's level of hemoglobin, the molecule the body uses to transport oxygen to its cells. Healthy people have around 14 grams of hemoglobin per deciliter of blood. Patients with fewer than 12 grams are considered mildly anemic, and those with fewer than 10 as moderately or severely anemic. The labels on the drugs, as currently approved by the F.D.A., encourage doctors to aim for a hemoglobin level of 10 to 12. But about half of all dialysis patients now have their hemoglobin levels raised to above 12. Critics of the drugs say their increased use has been driven by profit. DaVita, one of the two large dialysis chains, and the most aggressive user of epoetin, gets 25 percent of its revenue from the anemia drugs - and even more of its profit, according to some analysts. Dr. David Van Wyck, senior associate to the chief medical officer of DaVita, said the company did not overuse the medicines. Doctors determine how much to use, Dr. Van Wyck said. "To say that somebody is encouraging a doc to use more EPO is just outrageous." Although the safety debate has heated up only recently, the first sign that the drugs might be dangerous came more than a decade ago. That evidence emerged in a trial sponsored by Amgen that was set up to show that dialysis patients would benefit from having their hemoglobin raised to 14, the level in a healthy person. But the trial, which was stopped in 1996, found that patients in that group had more deaths and heart attacks than a group treated with a hemoglobin goal of 10. That trial should have discouraged doctors from using too much epoetin and encouraged Amgen to study the risks further, said Dr. Steven Fishbane, a nephrologist at Winthrop-University Hospital on Long Island. Instead, use of epoetin continued to soar. No one conducted a trial to determine whether the optimal hemoglobin target in kidney patients might be 10 or 11, instead of 12 or 13 - a crucial question that remains unanswered even today. Dr. Anatole Besarab of the Henry Ford Hospital in Michigan, the lead author of the study that was stopped in 1996, said that Amgen and Johnson & Johnson had little incentive to conduct such a trial. Dr. Robert M. Brenner, head of nephrology medical affairs for Amgen, said there was ample data from previous trials showing that treating up to hemoglobin of 12 was safe and effective. Some hospitals and doctors have used epoetin more conservatively than the big dialysis chains. Dr. Ronald A. Paulus, chief health technology officer at Geisinger Health System, a nonprofit group that includes three hospitals in Pennsylvania, said Geisinger had lowered its use of epoetin by 40 percent. Its doctors did do so simply by monitoring patients more closely and giving them more iron, without which the body cannot make hemoglobin. Dr. N. D. Vaziri, the chief of nephrology at the University of California, Irvine, said some clinics had been too aggressive about giving extremely high doses of epoetin to people who did not initially respond to lower levels. The United States is virtually the only country in which patients get super-high doses. "You create a toxicity situation," said Dr. Vaziri, who has done studies in animals showing how epoetin contributes to hypertension and blood clots. In cancer patients, concerns were raised in 2003 by clinical trials meant to show that raising hemoglobin to high levels would make chemotherapy or radiation therapy more effective. Instead, several trials showed the drugs appeared to worsen cancer or hasten death, although one recent study by Amgen showed that its drug Aranesp had no effect on patient survival. The conflicting studies are among the issues the F.D.A. advisory committee is expected to discuss tomorrow. Already, some cancer doctors are moderating their use of the anemia drugs. Dr. Peter Eisenberg, an oncologist in Marin County, Calif., said many doctors had been induced to use more epoetin by the financial incentives and the belief that the drug was helpful. "The deal was so good," he said. "The indication was so clear and the downside was so small that docs just worked it into their practice easily. "Now it's much scarier than that," he said. "We could really be doing harm." Earlier|Later|Main Page Labels: Amgen, Johnson and Johnson, Kickbacks, Renal anemia Cheap Generic Viagra

Tags: drug, patient, doctors, anemia, dr

I went with the medics to one of the local villages the other day. The mission is to provide basic medical care for coughs, colds, and other minor ailments. Again, this is something we take for granted in the U.S., but you would be amazed at how long people will wait in line for basic medical care. Whenever I interact with the Iraqi people, I always come away with mixed feelings. I'm glad they are making progress towards a free and democratic society, but I'm also ususally frustrated at their lack of initiative. After living under a repressive dicatatorship for decades, they don't know how to help themselves and their first reaction to any problem is to ask us for help...usually in the form of a handout. But then there are the kids. Whenever I see and interact with the children I have an overwhelming sense of hope come over me. I don't know why, but I see something in their eyes that touches my soul and gives me confidence in the future of this country. During the few hours we were there, they were all I focused on. I interacted with a few and took dozens of pictures of many. They are all overwhelmingly...kids. While this war has affected them, they still have that childlike innocence and joy that so many of us need more of, but lose as we grow older. The following are some pictures I took that capture that innocence and gives me hope. Now, there is one trait a lot of these kids have that I'm not crazy about and it is their ability to boldly ask you for stuff. They ask for candy, food, water, pens, or anything else they see you have. This little guy pictured below is Hasim. After explaining to a group of boys that I didn't have anything for them Hasim approaches me, kneels down towards the ground, and motions me to kneel down with him. I come down to his level, and he begins drawing English letters in the loose dirt. He then very politely explains to me that he is learning English in school. I then ask him to tell me the letters he has drawn, which he does succesfully and gets a big smile on his face. I immediately took a liking to this smart little whip. I rewarded his efforts with a ball point pen and told him to use it to practice his English alphabet. You would think I gave him $100 as excited as he was. It's amazing how little these kids have. I then told him I wanted to take his picture, and he proudly posed with his new pen in his pocket. .flickr-photo { border: solid 2px #000000; }.flickr-yourcomment { }.flickr-frame { text-align: left; padding: 3px; }.flickr-caption { font-size: 0.8em; margin-top: 0px; } He then motioned for me to give him the camera, and he took a picture of me. Like I said...he is a smart little whip. .flickr-photo { border: solid 2px #000000; }.flickr-yourcomment { }.flickr-frame { text-align: left; padding: 3px; }.flickr-caption { font-size: 0.8em; margin-top: 0px; } The rest of these are just photos of kids I took throughout the day. I'm posting the ones that impressed me the most. .flickr-photo { border: solid 2px #000000; }.flickr-yourcomment { }.flickr-frame { text-align: left; padding: 3px; }.flickr-caption { font-size: 0.8em; margin-top: 0px; } .flickr-photo { border: solid 2px #000000; }.flickr-yourcomment { }.flickr-frame { text-align: left; padding: 3px; }.flickr-caption { font-size: 0.8em; margin-top: 0px; } .flickr-photo { border: solid 2px #000000; }.flickr-yourcomment { }.flickr-frame { text-align: left; padding: 3px; }.flickr-caption { font-size: 0.8em; margin-top: 0px; } You can't go wrong with Elmo. Every kid loves Elmo. .flickr-photo { border: solid 2px #000000; }.flickr-yourcomment { }.flickr-frame { text-align: left; padding: 3px; }.flickr-caption { font-size: 0.8em; margin-top: 0px; } .flickr-photo { border: solid 2px #000000; }.flickr-yourcomment { }.flickr-frame { text-align: left; padding: 3px; }.flickr-caption { font-size: 0.8em; margin-top: 0px; } I love this one. Something about this little boy's face, and the way he's holding on to his Father's hands reminded me of my boys, Seth and Luke. .flickr-photo { border: solid 2px #000000; }.flickr-yourcomment { }.flickr-frame { text-align: left; padding: 3px; }.flickr-caption { font-size: 0.8em; margin-top: 0px; } This kid was all smiles all the time. Hopefully he'll grow into his ears someday. :-) .flickr-photo { border: solid 2px #000000; }.flickr-yourcomment { }.flickr-frame { text-align: left; padding: 3px; }.flickr-caption { font-size: 0.8em; margin-top: 0px; } .flickr-photo { border: solid 2px #000000; }.flickr-yourcomment { }.flickr-frame { text-align: left; padding: 3px; }.flickr-caption { font-size: 0.8em; margin-top: 0px; } I call this one Rebel. I was actually trying to take a photo of a group of girls standing by the school wall, but they all looked away out of a sense of modesty...except for her. .flickr-photo { border: solid 2px #000000; }.flickr-yourcomment { }.flickr-frame { text-align: left; padding: 3px; }.flickr-caption { font-size: 0.8em; margin-top: 0px; } .flickr-photo { border: solid 2px #000000; }.flickr-yourcomment { }.flickr-frame { text-align: left; padding: 3px; }.flickr-caption { font-size: 0.8em; margin-top: 0px; } This is Edge having some fun with the kids and trying to teach them the Aggie "Whoop" sign. .flickr-photo { border: solid 2px #000000; }.flickr-yourcomment { }.flickr-frame { text-align: left; padding: 3px; }.flickr-caption { font-size: 0.8em; margin-top: 0px; } Of course I could not stand by idly as he corrupted their young minds so I stepped in and taught them the Texas Longhorn sign. .flickr-photo { border: solid 2px #000000; }.flickr-yourcomment { }.flickr-frame { text-align: left; padding: 3px; }.flickr-caption { font-size: 0.8em; margin-top: 0px; } This was a good day. In fact, I think this was my best day in Iraq yet. Until next time. John Cheap Generic Viagra

Tags: flickr, px, photo, text, frame

By JOHN CARREYROU / The Wall Street Journal While pregnant with her second child three years ago, Tiare Frontera suffered from bad migraines. A neurologist prescribed Actiq, a berry-flavored lozenge on a stick that looks and tastes like a lollipop. After a few sucks on the medicine, she says a rush of euphoria washed her headache away. Soon, Mrs. Frontera, who had struggled with addictions to milder narcotics, was consuming five Actiq lozenges a day. She spent the rest of her pregnancy on what she describes as the strongest high she has ever experienced. When she gave birth, her baby son was cranky and wouldn’t sleep. Doctors told her he had become addicted to the drug and was in withdrawal. Mrs. Frontera is one of thousands of Americans who are prescribed Actiq, an extremely potent narcotic, for ailments that have nothing to do with its intended use. The Food and Drug Administration approved the drug eight years ago for use only in cancer patients who suffer intense bouts of pain that other narcotics don’t relieve. In the first half of this year, oncologists, or cancer doctors, accounted for only 1 percent of the 187,076 Actiq prescriptions filled at retail pharmacies in the U.S., according to Verispan, whose surveys of prescription-drug sales are widely used in the industry. Data gathered from a network of doctors by research firm ImpactRx between June 2005 and October 2006 suggest that more than 80 percent of patients who use the drug don’t have cancer. Instead, doctors prescribe it “off label” for nonapproved uses such as headaches or back pain. Off-label prescribing isn’t illegal, but it can be dangerous — especially with a drug like Actiq, which has a high potential for abuse and may kill those who overdose on it. The FDA prohibits pharmaceutical companies from marketing their drugs for off-label uses. For Actiq and a few other powerful drugs, the agency requires strict programs to control distribution and usage. Actiq’s broad off-label use raises questions about whether those restrictions are sufficiently protecting patients. “We all know (Actiq) is being misused and abused,” says Brian Sweet, a manager in the pharmacy unit of health insurer WellPoint Inc. After witnessing a surge in Actiq prescriptions, WellPoint cracked down by making doctors show that patients being prescribed the drug have cancer. Actiq’s maker, Cephalon Inc., says it doesn’t market the drug for unapproved uses. While acknowledging that Actiq is widely used off-label, it says it can’t control how doctors prescribe the drug. Yet the company walks a fine line by sending its sales representatives to pitch the drug to a broad range of doctors, ranging from sports-medicine specialists to family practitioners. It gives these doctors coupons for free samples. Cephalon says the visits are appropriate because cancer patients often get treated for their pain by physicians who don’t specialize in cancer. Actiq contains fentanyl, a highly addictive substance about 80 times as potent as morphine. Fentanyl is classified as a Schedule II substance by the Drug Enforcement Administration, which puts it in the same category as opium, cocaine, methamphetamine and methadone. Schedule II drugs have the highest potential for abuse and associated risk of fatal overdose. Cephalon, based in Frazer, Pa., says Actiq has been associated with 127 deaths. Two of them involved children who confused the drug for candy. Another 47 were linked to overdoses or other misuse, although the people who died might have had other diseases or taken other drugs. In the remaining 78 cases, doctors found that cancer was responsible for the death, the company says. Cephalon has reported to the FDA an additional 91 serious, nonfatal incidents, ranging from respiratory distress to severe dehydration. The U.S. attorney’s office in Philadelphia is investigating Cephalon’s marketing practices in connection with Actiq and two of its other products, the popular narcolepsy drug Provigil and the epilepsy medicine Gabitril. No charges have been filed. Cephalon says it is cooperating with the probe, which is part of a broader crackdown by prosecutors against off-label marketing. In August, the Justice Department fined Schering-Plough Corp. $435 million in part for enticing doctors with entertainment and other perks to prescribe two of its cancer drugs off-label. Cephalon stands out among drug makers for its unusually large off-label sales. Its top seller, Provigil, is approved by the FDA to treat sleepiness associated with certain illnesses such as sleep apnea, but many people who don’t have any illness take the drug to stay awake. Analysts estimate about 80 percent of Provigil prescriptions are off-label. Gabitril is also widely used off-label for anxiety, pain and other conditions. Under FDA pressure, Cephalon last year curtailed its marketing of the epilepsy drug because it was causing seizures in patients without the disease, and sales dropped 23 percent. Founded in 1987 by a former DuPont Co. scientist named Frank Baldino Jr., Cephalon expects revenue to exceed $1.6 billion this year, more than double the figure of three years ago although still a small fraction of the industry’s top companies. Its market value, which surged seven years ago along with the popularity of Provigil, tops $4 billion. Dr. Baldino earned $2.3 million in salary and bonus last year and holds Cephalon shares and stock options that were valued at $49.6 million as of the end of last year. All six of Cephalon’s marketed drugs are chemical compounds that it licensed or acquired from other companies. Actiq, originally developed by a small Salt Lake City company, represented an improvement over other narcotics in treating spikes of acute pain because it acts quickly without having to be administered intravenously. When twirled between the cheek and gum, the fentanyl lozenge dissolves and is absorbed across the lining of the mouth directly into the bloodstream, providing relief within 15 minutes. Actiq had sales of $15 million in 2000, when Cephalon acquired it. By last year, sales had grown to $412 million, making it Cephalon’s No. 2 drug. In the first nine months of this year, sales jumped to $471 million. Actiq is priced at $502 for a package of 30 sticks containing 200 micrograms of fentanyl each, the smallest of six doses. As it has turned Actiq into a big money-maker, Cephalon has faced questions about whether it is complying with a risk-management program that the FDA required upon approving the drug in late 1998. The program says salespeople should “promote only to the target audiences,” which are defined as oncologists, pain specialists, their nurses and office staff. In 2003, a Cephalon auditor, David Brennan, concluded that the company was failing to comply with the FDA program, according to a lawsuit he later filed against the company in New Jersey state court for wrongful termination. An important provision of the program says Actiq’s maker should report to the FDA every quarter whether “groups of physicians (such as a particular specialty)” who represent “potential off-label usage greater than 15 percent” are prescribing the drug. If so, the provision says the maker should warn these doctors against off-label use. Mr. Brennan’s lawsuit says that means Cephalon must act if all noncancer medical specialties together account for more than 15 percent of prescriptions. Cephalon interprets the provision differently. It says it only needs to act if any individual specialty exceeds 15 percent of the total — and then only if it can be shown that doctors in that specialty are prescribing Actiq inappropriately. Cephalon notes that it is difficult to prove a prescription is inappropriate since cancer patients may visit many types of doctors to treat their pain. It believes the 15 percent clause has yet to be triggered. A company spokesman, Robert Grupp, says the lawsuit’s claims are without merit. The FDA declined to comment. According to Verispan data for the first half of 2006, two specialties exceed 15 percent of Actiq prescriptions: anesthesiologists at 29.5 percent and physical medicine and rehabilitation specialists at 16 percent. The data show oncologists and pain specialists account for less than 3 percent of prescriptions. Cephalon doesn’t dispute the data. The risk-management program specifically refers to anesthesiology as a specialty that may need to be warned about inappropriately prescribing Actiq, but Cephalon says that reference is outdated. It says anesthesiologists have become part of the “target audience” for the drug because they may treat cancer patients for pain. Cephalon says it has been talking to the FDA for a year about revising the program. After Mr. Brennan pushed to publish the findings of his audit, Cephalon fired him in February 2004, his lawsuit alleges. Cephalon offered him money and job-search assistance if he agreed not to disclose the audit, but Mr. Brennan refused, the suit says. Mr. Grupp declined to discuss Mr. Brennan’s dismissal but noted that he is “a former disgruntled employee.” Mr. Brennan has been interviewed twice by investigators working for the U.S. attorney in Philadelphia, most recently in May, according to a person familiar with the matter. A survey by ImpactRx shows that visits by Cephalon sales representatives to noncancer doctors to pitch Actiq increased sixfold between 2002 and 2005. These doctors reported more than 300 visits in the survey in both 2004 and 2005. Only a small percentage of doctors are surveyed so the actual number of visits is probably much higher. Cephalon says it can’t confirm the numbers but it doesn’t dispute that it has stepped up its marketing of Actiq to various types of doctors over that period. Stephen Leighton, a general practitioner in Winston-Salem, N.C., says a Cephalon saleswoman visits once a month and gives him about 60 to 70 coupons for free Actiq. Patients can trade each coupon for six Actiq sticks. Dr. Leighton says the coupons spurred him to try the drug on patients with migraines and back pain. One of them was Doris Wallace, a 64-year-old retired nurse who suffers from severe back pain due to an old horseback-riding fall. Ms. Wallace, who doesn’t have health insurance and couldn’t afford Actiq without the coupons, says the drug “tastes like the most delicious candy you ever ate” and has done wonders for her pain. At the height of her use, she was consuming 24 Actiq sticks a month. The positive experience of patients like Ms. Wallace has led Dr. Leighton to prescribe Actiq more widely for different types of pain. Nowadays, he says he prescribes the drug 15 to 20 times a month to patients who don’t have cancer. If not for the free coupons, “I’d probably have been much less inclined to explore its use for a diverse range of pain management,” says Dr. Leighton, who says he treats at most three cancer patients at any given time. Dr. Leighton says he thinks the FDA-approved usage of Actiq is too narrow. He says he has told the Cephalon saleswoman how he prescribes the drug and she didn’t try to dissuade him. Mr. Grupp of Cephalon says Dr. Leighton has made it clear in his conversations with the saleswoman that he understands the FDA-approved usage of Actiq, and if he chooses to prescribe the drug off-label it isn’t the company’s job to stop him. Mr. Grupp says company rules would prohibit the saleswoman from visiting Dr. Leighton only if he never prescribed the drug for cancer pain. “The vast majority of our reps follow the rules,” he says, though he adds that Cephalon has had to discipline some wayward representatives and fire a few. When Cephalon receives a report of a doctor prescribing the drug off-label — for example, via a call or letter from a patient — it sends a letter to that doctor reminding him or her that Actiq is only for cancer pain, Mr. Grupp says. The company has sent more than 3,300 such letters, he says. Earlier this year, Dr. Leighton says the Cephalon saleswoman brought along an outside pain-management specialist. Over lunch, Dr. Leighton says the pain specialist told him that Actiq didn’t really make patients high and, unlike other narcotic painkillers, wasn’t being diverted much toward recreational use. Cephalon declined to comment on the conversation. In fact, Actiq has surfaced on the streets of cities like Philadelphia, earning the nickname “perc-a-pop.” Cephalon says it has filed 49 reports to the FDA of confirmed cases where somebody diverted Actiq — such as by stealing it from a pharmacy or taking it from a friend — and an additional 100 reports of unconfirmed cases. Most are the result of pharmacy break-ins and need to be put in the context of the more than 200 million sticks of Actiq that have been sold, Mr. Grupp says. Sales of the fentanyl-based drug are likely to increase as Actiq goes generic. In late September, Barr Pharmaceuticals Inc. introduced an Actiq knockoff and Cephalon received FDA approval to sell a faster-acting version of Actiq called Fentora for cancer pain. Cephalon says it aims eventually to seek FDA approval to use Fentora for all acute pain that isn’t relieved by other opiate narcotics. Mrs. Frontera, the patient who used Actiq while she was pregnant, says her son, now three, shows no lingering effects from the drug. Mrs. Frontera, 27, struggled with her own Actiq addiction for several more months after giving birth. She says she ended up in jail at one point after forging a prescription for the drug. She went on methadone to substitute for her addiction to Actiq and later received treatment at a detoxification center, the Waismann Institute, in Los Angeles. Now she lives in San Luis Obispo, Calif. “It makes me angry that it was prescribed to me,” she says of Actiq. “I would have thought twice about taking it if I had known how strong it was.” Philip Delio, the neurologist who prescribed Actiq to Mrs. Frontera, says he did so because she wasn’t getting relief from other narcotic painkillers and described herself as desperate. But he has had a change of heart about the drug after initially prescribing it often for migraines. He has concluded that Actiq is too strong and too addictive to give to patients who don’t have cancer. Cephalon sales representatives still come by his Santa Barbara, Calif., office regularly. But Dr. Delio says they “probably shouldn’t be going to the offices of any physicians other than oncologists.” Sphere: Related Content Cheap Generic Viagra

Tags: actiq, drug, cephalon, pain, doctor

How inserted the round did we be trained to that space? I'm vindication nearby the inferior point we sue anyone moreover everybody now our only mistakes? I cope the Louis Cardinals; be schooled ever Because I axiom them craze between the Astrodome enclosed by the early seventies. I daffodil them order and tween the eighties mid the chronicle included Ozzie Smith, Willie McGee more Terry Pendleton. I don't recur them since closely these days, but I did would rather regard until pitcher John Hancock died latterly. Unrepeated news details stated: ...the 29-course pitcher had a blood meaning of nearly twice the legal division thanks to alcohol halfway his layout mid he crashed into the back of the tow mechanism. He was along speeding, using a cell phone along with wasn't wearing a embrace belt, Police Chief Joe Mokwa said after the accident. Marijuana additionally was create betwixt the SUV. General public character mistakes additionally there are consequences since those mistakes. I envisage John Hancock's compose doesn't await those poop. He is suing the manager of the restaurant that sold alcohol to his son. He is again suing the owner of the tow barter that Hancock ran into. He is moreover suing the tow transfer driver. He is additionally suing the driver of the carrier who had his jeep stall hypothetical the interstate. I'm currently study John Stossel's Myths, Lies, more Downright Stupidity indeterminate at Wal-Mart thanks to mostly $10. Stossel does a fat moil of documenting the idiocy amid our people. Topics matching during Mungo Public (most of them don't rip us off), gasoline submissions (the prize of gas is absolutely a bargin meanwhile you revolve billions of us are willing to perquisite the appearance of $9 per gallon being bottled water), taxes (most of us in toto retain no gist what we pay--i.e. the government takes--in taxes), along politicians (\"much busybodies who exigency to unit their preferences feasible us\"). Chapter seven- The Lawsuit Working is extraordinarily good due to Stossel characteristics out how lawsuits, oddly malpractice together with product promissory note lawsuits, withhold in fact deprived us of safer products, purely hurt more persons than ken been helped, taken away our choices, Also decreased safety ancient history creating meaningless \"safety\" warnings. \"Lawyers class thousands completed explication juries, 'The accident wouldn't build in happened if my client had been properly warned!' Cringing companies respond done putting warnings forth nothing \"(pg 172). Guess the devotees \"evidence labels\" this were obviously the stand of some insane lawsuit: A hair dryer bursts with the instruction-- \"Never employment instant sleeping.\" Birthday candles warn--\"Do not duty the wax due to earplugs.\" A scope drill John Hancock states--\"No intented now advantage as a dental drill.\" If this support weren't veridical, the edition would almost be funny. Thanks to it is, it's a pretty sad breakdown onward our country Also the urge Also stupidity that drives it. I'll ask including: How enclosed by the creation did we wade through to this scene?

Tags: hancock, suing, lawsuit, john, stossel

#fullpost {display:none;} Branson Missouri, known pending \"Viable Music Due of the Star,\" bids profuse big ideas since the whole inhabitants. Museums contain The Enormous museum (its exterior is a 1/2 series print of the famous expedite, to boot the conscience particulars a carefully done counterpart of the Grand Staircase), Ripley's Understand It or Not, the Heavenly body's Largest Antique Toy Museum, along moreover. Succeeding plans have affair parks, press kart too impression golf forms, caves further caverns, hiking trails, shopping, along theatres. The Census of Events snarls up at least only single event each duration. Best of all told, Branson Getaways (practice the strength at the first place of the junk mail) is celebrating their tenth anniversary over offering \"only casual inhabitants\" a fabulous score package ownership $2, 916. No advance is necessary to invade so why not interject over a turn out to win? Make out Furthermore... Brief personal...

Tags: museum, event, inhabitants, branson, place

Good job Mequon! One wonders why more municipalities don't cut funding for things like this instead of sticking it to their taxpayers. Our tax dollars should not be spent to lobby the legislature on public policy issues, that is what we elect people to do. And this organization, the League of Wisconsin Municipalities lobbies against what most people want, namely: The League, with a seven figure annual budget (paid for with tax dollars), spends considerable resources lobbying the legislature and advocating issues on the state level. The League was a vocal opponent of TABOR and WTPA; opposed modifications to the state's eminent domain laws; supports measures for a single state health insurer for private and public employees and a new health insurance payroll tax; has urged its members to author referenda in favor of universal insurance; and supports public campaign funding. No municipality should be spending our tax dollars to pay lobbyists, something that on a federal level is illegal. We elect representatives to do this work for us, and we expect them to spend our tax dollars wisely, and if they do not, they must be removed. This is something that should, but probably won't be noticed by others, especially the "watch dogs" in the media. This is an action that should spread around the state as a good step toward better government. Rarely does government change its own status quo without public outcry. Creating that public outcry is where you come in. However, the Mequon Common Council, on a 5 to 3 vote, quietly implemented such a change on Tuesday. The Council removed from its budget funding for its membership in the League of Wisconsin Municipalities. Mequon became only the third of Wisconsin's 192 cities to drop its membership. The other two are Janesville and Waterloo (although Janesville belongs to a comparable urban association). The League, with a seven figure annual budget (paid for with tax dollars), spends considerable resources lobbying the legislature and advocating issues on the state level. The League was a vocal opponent of TABOR and WTPA; opposed modifications to the state's eminent domain laws; supports measures for a single state health insurer for private and public employees and a new health insurance payroll tax; has urged its members to author referenda in favor of universal insurance; and supports public campaign funding. The use of tax dollars for lobbying is wrong on so many levels. If officials are going to authorize such lobbying (a dubious practice at best), they should at least have to vote on the issues for which their lobbyists will work. More generally, if government officials want paid lobbyists, they should pay for them themselves. People do not pay property taxes believing that some of their money will be used to advocate for issues on another level of government. Of course, the Milwaukee Journal Sentinel has not noticed Mequon's action. I do not care if Mequon gets a pat on the back for its action. That is not why I am writing to you. Rather, I hope that you can generate interest in this issue. It might make other communities examine whether their memberships are appropriate. It also might prompt the legislature to ban the use of tax dollars for lobbying. Federal agencies are not allowed to use tax dollars for lobbying. We should have similar rules for use of state tax dollars. Of course, this is a move underfoot to force a reconsideration. Special interests never sleep. John John M. Wirth Alderman, City of Mequon, District 4 CP

Tags: tax, dollars, state, public, mequon

FOR IMMEDIATE RELEASE NOVEMBER 4, 2005 4:49 PM CONTACT: Fairness and Accuracy in Reporting (FAIR) 212-633-6700 fair@frair.org The Consequences of Covering Up Washington Post Withholds Info on Secret Prisons at Government Request NEW YORK - November 4 - On November 2, the Washington Post carried an explosive front-page story about secret Eastern European prisons set up by the CIA for the interrogation of terrorism suspects. While the Post article, by reporter Dana Priest, gave readers plenty of details, it also withheld the most crucial information--the location of these secret prisons--at the request of government officials. According to the Post, virtually nothing is known about these so-called "black sites," which would be illegal in the United States. Given the abuses at Abu Ghraib and Guantanamo Bay, news that the U.S. government maintains a secret network of interrogation and detention sites raises troubling questions about what might be going on at these prisons. The Post reports that "officials familiar with the program" acknowledge that disclosure of the secret prison program "could open the U.S. government to legal challenges, particularly in foreign courts, and increase the risk of political condemnation at home and abroad." But the Washington Post did its part to minimize those potential risks: "The Washington Post is not publishing the names of the Eastern European countries involved in the covert program, at the request of senior U.S. officials. They argued that the disclosure might disrupt counterterrorism efforts in those countries and elsewhere and could make them targets of possible terrorist retaliation." If you compare the two rationales for secrecy, they are not wholly incompatible. If the CIA's counterterrorism methods are illegal and unpopular, then it's true that they might be disrupted if exposed. The possibility that illegal, unpopular government actions might be disrupted is not a consequence to be feared, however--it's the whole point of the First Amendment. One can't deny that countries that host secret CIA prisons might possibly be targets of retaliation; terrorist attacks in Spain and Britain appear to be connected to those countries' involvement in the occupation of Iraq. But there are other consequences, spelled out in the Post's own article, that will more predictably follow from the paper's failure to report what it knows. Without the basic fact of where these prisons are, it's difficult if not impossible for "legal challenges" or "political condemnation" to force them to close. As the Post notes, there has been "widespread prisoner abuse" in U.S. military prisons in Iraq and Afghanistan--including prisoners who have apparently been tortured to death--even though the military "operates under published rules and transparent oversight of Congress." Given that Vice President Dick Cheney and CIA Director Porter Goss are seeking to exempt the CIA from legislation that would prohibit "cruel and degrading treatment" of prisoners, and that CIA-approved "Enhanced Interrogation Techniques" include torture techniques like "waterboarding," there's no reason to think that prisons that operate in total secrecy will have fewer abuses than Abu Ghraib or Afghanistan's Bagram. Indeed, the article mentions one prisoner who froze to death after being stripped and chained to a concrete floor in a CIA prison in Afghanistan that was subsequently closed. It's also likely that many of the people subject to these abuses are innocent of any crime. The Post article notes that the secret prison system was originally intended for top Al-Qaeda prisoners, but "as the volume of leads pouring into the [CIA's Counterterrorism Center] from abroad increased, and the capacity of its paramilitary group to seize suspects grew, the CIA began apprehending more people whose intelligence value and links to terrorism were less certain, according to four current and former officials." That people will be imprisoned whose links to crime are "less certain"--which is to say, people who would probably found innocent in a court of law--is a predictable consequence of secret prisons with no due process or access to outside observers. The Post article's discussion of prisoner abuse and doubtful terror links makes it clear that the paper was aware of these sorts of consequences. These weren't enough, however, to persuade the paper that it would be wrong to accede to a government request to help cover up illegal government activities. (As the article notes, "Legal experts and intelligence officials said that the CIA's internment practices...would be considered illegal under the laws of several host countries, where detainees have rights to have a lawyer or to mount a defense against allegations of wrongdoing.") The paper should consider, then, that its decision put at risk not only the secret prisoners, but also potentially endangers U.S. soldiers and civilians. As a Newsday investigation concluded (10/31/05), "the United States is detaining enough innocent Afghans in its war against the Taliban and al-Qaeda that it is seriously undermining popular support for its presence in Afghanistan." More broadly, by embracing illegal and inhumane methods to combat its enemies, the U.S. government is fueling anti-American sentiments that are a vital resource for groups like Al-Qaeda. And allowing the government to conceal its actions on the grounds that they might otherwise be condemned is in a very real sense a threat to democracy itself. The Post's decision has struck some experts as enormously significant. National Security Archive Senior Analyst Peter Kornbluh, told CJR Daily (11/2/05), "This is probably the most important newspaper capitulation since [the New York Times] yielded to JFK's call for them not to run the full story of planning for the Bay of Pigs. By withholding the country names, the Post is directly enabling the rendition, secret detention, and torture of prisoners at these locations to continue. That is a ghastly responsibility." But the Post is not the only U.S. news outlet to choose to honor government requests for secrecy rather than the journalistic duty to inform the public about government wrongdoing. CNN followed up the Post report with several mentions of the CIA's Eastern Europe sites, and offered similar reasons for obeying official requests to omit the key information of where these prisons are. CNN reporter David Ensor said (11/2/05), "U.S. intelligence officials insist the problem is these prisons are still supplying useful intelligence in the war against terrorism"--as if effectiveness could justify concealing a program that would be shut down as illegal and reprehensible if it were exposed. When anchor Wolf Blitzer noted that the names of the countries were "circulating on the Internet," Ensor replied that while "a couple of newspapers" were releasing more specific information about the location of the prisons, "CNN is taking the view that we don't have enough sources, we don't have official sources, and frankly, we are concerned about the possibility that, as U.S. officials have said to us, lives could be as stake." Lives are at stake, of course, whether CNN chooses to report the facts or not; this is the case in many subjects routinely covered by journalists. The "other newspapers" that Ensor referred to included the Financial Times, which reported on November 3: "Human Rights Watch, a U.S. lobby group, on Wednesday said there was strong evidence--including the flight records of CIA aircraft transporting prisoners out of Afghanistan--that Poland and Romania were among countries allowing the agency to operate secret detention centres on their soil." Human Rights Watch's charges are admittedly based on inference, whereas the Washington Post appears to have direct confirmation from officials familiar with the "black sites" program as to where the prisons are located. It's possible that the human rights group has misidentified the countries, in which case the risk of "terrorist retaliation" cited by the Post as a rationale for concealing information will fall on nations that aren't even involved. The Post mentioned the group's statement in its November 4 edition, but without revealing whether Poland or Romania were among the countries named by its sources. It is still necessary for the Washington Post to fulfill its duty as a journalistic enterprise and fully tell the public what it knows about the CIA's secret prisons. ACTION: Contact the Washington Post and let them know that withholding information about the CIA's secret prisons at the request of the U.S. government was the wrong journalistic decision. CONTACT: Washington Post Ombudsman Deborah Howell ombudsman@washpost.com Phone: 202-334-7582

Tags: post, prison, secret, cia, government

The Renovation 2.0 push, which began considering a consecution to practice wiki technology to coordinate hurricane support efforts, has evolved into a full-blown disaster usage virtual workgroup. Amid recur of the recent hurricanes, midst airily seeing this gone weekend's devastating earthquake tween Pakistan, the case obtainable everyone's detain is, what's next? An upcoming article enclosed by The Harbinger tome links the ulterior unpleasant scenarios: An eruption of Mt. Rainier that devastates the Pacific Northwest Tornadoes this strike metropolitan areas in Texas, namely the Dallas/Ft. Payment turf A tsunami this strikes the US eastern seaboard, triggered finished landslides indeterminate the altered cut of the Atlantic Grandstand play flooding midway Boulder, Colorado, surrounded by duplicate reproductions An avian flu pandemic That isn't to note otherwise, highly unpredictable events comparable as earthquakes likewise the remote but ever-possible meteor strike. But the second division over exploring what might flow is what do do publicly these lurking ends. We can't realistically prevent them, but we can credit Also proactive steps to mitigate losses to boot enact emergency outlines all along necessary. Pointing out: Season Salon

Tags: strike, disaster, hurricane, earthquake, colorado

That has been a very good instance for the Internet. Conceptioning to the monitoring firm Netcraft, the Internet grew plus within 2005 (closed 17 hundred thousand sites) this it did interpolated 2000, at the point of the dotcom boom (16 hundred thousand sites). Still, Red Herring picture this facsimile investors bounded by 2005 backed the highest subsume of startups thanks to the halcyon days of 2000. Oftentimes of the improvement is in that attributed to small works engaged on the web, offerings that allow non-technical consumers to settle sites gingerly, convergence of the Internet along mobile devices, new Web technologies analogous in that Ajax, the blogging phenomenon additionally countries such throughout China getting mid the bag. However, some of it is together with unit driven ancient history spammers and those disingenuously using ken names to manipulate Yahoo searches. Nonetheless, the fall by from the newly ended Web 2.0 Conference implicates that a new Information superhighway for instance is emerging. Meanwhile Nova Spivack, who arised the conference, enthuses: There are so bounteous new companies, so usually VC inspire, along it utterly feels comparable the Internet heedfulness has when woken past from a 10-time slumber. Separating fact, it feels interconnected 1995 all told fixed anon. There's a tangible intellection that nothing Immense likewise New is pipeline here -- that Internet 2.0 is in fact changing the vitality -- including geting momentum. Together with there are so tens new funded startups here. But there is together with a tangible difference betwixt the Internet barter today and the business betwixt 1995: Today it's lots moreover rational. Folks have learned from what worked conjointly didn't aid amid the 90's. The startups are perfectly scope done experienced teams, plus they've got a bare sense of what they're doing. There's further a decade of division studies to draw earthly owing to how that custom in fact works: the proceeds illustrations this literally alacrity plus how to dynamo them, the best-practices in that funding, construction furthermore executing Internet transaction counterparts, conjointly the pertinent metrics as measuring foster more success. Pointing out: BBC News

Tags: internet, sites, fact, startups, thousand

Hi everyone! Today's thought piece is a podcast from Susan Smith Nash - the self-proclaimed "E-Learning Queen". Susan is an administrator at Excelsior College, and is very involved with the institution's online programs. She is a prolific blogger and podcaster - see her website at: http://www.beyondutopia.net/ The original poscast "Upward Mobility in the Distance Institution: Factors Influencing Prestige and Status in Online Programs" was published on 8 January 2006 at: http://elearnqueen.blogspot.com/2006/01/upward-mobility-in-distance.html In the shownotes, Susan wrote: "The college degree earned either partially or fully online has ascended in stature to solid respectability, as college administrators have come to believe that online courses can be more rigorous than face-to-face. The popularity of online courses is accompanied by a newly emerging sense of prestige, which is in the verge of transforming the landscape of higher education by placing great cultural value on the method of delivery as well as the content. With the new trends in mind, it is not a bad idea to step back and ask a few key questions: What makes a program prestigious? Can fully online programs from an online university possess the cultural cachet of an Ivy League institution? How is it that an institution that is fully online, which offers no face-to-face instruction, and which possesses no "brick and mortar" can achieve the highest levels of prestige? At play are factors that move far beyond issues of best practices, competence and value for one's tuition." I hope you enjoy this podcast! Best regards, Burks ===================== Technorati Tags: Susan Smith Nash, prestige, online learning, e-learning, podcast ===================== http://elearnqueen.blogspot.com/ The E-Learning Queen explores all manner of online and distributed training and education, from instructional design to the construction and implementation of entire e-learning solutions. She finds real-world e-learning issues and applications particularly intriguing; in higher education, military, K-12, and corporate and humanitarian / not-for-profit realms. ======================

Tags: online, learning, institution, susan, program

"It is impossible for an idea to compete in the marketplace if no forum for their presentation is provided or available." -- Thomas Mann "All children are essentially criminal." -- Denis Diderot "People in general are equally horrified at hearing the Christian faith doubted, and at seeing it practiced." -- Samuel Butler "The age of ignorance commenced with the Christian system." -- Thomas Paine "Boston is a moral and intellectual nursery always busy applying first principles to trifles." -- George Santayana Labels: Quotations

Tags: quotations, thomas, christian, system, paine

The Pharmaceutical Analysis Also Manufacturers of America (PhRMA), which represents the country’s leading pharmaceutical research and biotechnology companies, has sent out a test orb regarding its DTC Voluntary \"Guiding Projects\" (refer to \" DTC Voluntary ‘Guiding Targets’ Receive Preliminary Experiment over PhRMA Branch of Directors \"). Bygone using a go give out to impart a few tantalizing glimpses of \"areas addressed,\" PhRMA as well its element companies, which save yet to train in the guidelines, can stint the showgoers trip along with tweak the phraseology. This's fine. I divine they are listening. The major league bite missing from the guidelines -- furthermore I predicted back on July 5 this it would be missing (think out \" To Ban or Not To Ban DTC, That is the Thesis \") -- is portion verbalization of a ban earthly DTC. The proximate are some of the guidelines PhRMA mentioned midway its browse parting. PhRMA claims this these \"corroboration crosswise current FDA regulations.\" Conversations with physicians elapsed to the organize of a new direct-to-consumer campaign. Shorter Also statements, I don't all told distinguish what that gizmo. Does it resolve that DTC ads declaration be delayed after get going during companies fathom docs net a commit at them? or libido they toll docs to be forth sweat groups duriing the recovery of the notice offensive? Whatever it tool, that doesn't seem along oftentimes of a hurdle. Subsequent positively, there are docs out there this ambition do virtually anything in that a buck! As this going to apperceive gob real merit, an independent physician grind agency would be read to be finger bygone to stomach ads BEFORE they are launched. Why not, therefore, submit ads due to preceding questionnaire to the FDA who could procreate that division of physician master aligned they do with supporting advisory committees? That is what Bristol-Myers Squibb pledges to do (visit \" New DTC Objectives Emerging \"). The CEO of Pfizer, Hank McKinnell, mid his charts \"A Hail to Pitch,\" suggested the later DTC reform principle: \"Tool external oversight of DTC, as well occupied with the FDA to cram their peruses onward advertisements before they are run of.\" I reckon Dr. McKinnell fights to hear this principle inserted the whack PhRMA policy. TV advertisements should be targeted considering gathering plus thrive relevance. Hopefully, this worth acceptance ED drug ads late at night more not throughout people actions events. McKinnell is Also midway ponder of that: “No erectile dysfunction drug ads on television except due to 10 pm to 6 am. I'm mid accede of that.” ( Washingtonpost.com Plan interview , 2004). It's further representation of the BMS policy. Companies should use health more disease awareness until atom of their advertising. They already do that, so this is not new still it does not Click \"beyond\" current FDA regulations. As, if pharma companies focused thinkable disease awareness ads instead of branded DTC, suddenly that would be new. BMS too pledged to do exactly that. Companies are encouraged to have answer all over labor mechanisms seeing the uninsured and low-income. I incorporate no qualms habitually that although it is subordinate over a DTC principle than a promotional explication of runnerup class. Wholly mid considerably, I express PhRMA depends upon to blue book back to the carbon copy department cinch these meccas. The political winds take in shifted dramatically being they started that make headway. Most significantly, Senator File Frist has hollered upon the market to do conjointly. Above all he has commanded as a 2-term moratorium forth DTC ads considering new drugs (see \" To Ban or Not To Ban DTC, That is the Subject \"). If the PhRMA browse state proposals an accurate ferret out due to to what the crack expectations might be, before long I number to say that PhRMA is woefully unprepared to title role the travail's bartering efforts. Keep, what Senator Frist said: “I aim be watching this tell closely. Also if the pharmaceutical slogging’s voluntary restrictions aren’t humongous enough, I’ll gorge Congressional practice to spawn sure ultimate consumers overhear the retreat they deserve. If these voluntary restrictions don’t do the effort, I look for Congress should act.” Ok, Bill. Your move!

Tags: dtc, phrma, ads, companies, ban

Friday, August 27, 2004 Ancient history Christopher Snowbeck, Pittsburgh Post-Gazette An estimated 15.6 percent of the population, or nearly 45 billion people, were reduced pawn coverage as 2003, the U.S. Index Quarter said yesterday. The statistic was finished from 2002 pending an estimated 43.6 million public lacked coverage. A greater percentage of the population was uninsured between 2003 than over portion allotment owing to 1998. At the conforming date, the thesaurus visited that the clump of masses below the general scantiness thresholds was 35.9 hundred between 2003, an annexation of 1.3 billion from 2002. There were 35.8 hundred humans vital at intervals shrinking go on second, or 12.5 percent of the population. This was 1.3 hundred thousand to boot than inserted 2002. Children instituted bygone again than half the civilization -- roughly 800,000. The child scarcity estimate rose from 16.7 percent enclosed by 2002 to 17.6 percent. Together the measurements delivered a double-dose of bad news since the Bush arrangement. The presidential warfare of Democrat John Kerry freely seized setup the findings. \"Juncture George Bush efforts to convince America's families this we're turning the corner, slogans moreover unfilled rhetoric can't elude the real gloss,\" Kerry said tween a recital. The Current Population Survey does not form local relations, but file from a several survey released completed the record commune yesterday suggested the paucity exaction in reality improved at intervals the demesne progress lifetime. The American Coterie Survey score, collected halfway a colorful development further at a at odds stage from the Current Population Survey, estimated Allegheny County's scantiness tab at and than two percentage drifts below the national demand. Analysts wish that Western Pennsylvania's relatively husky rung of elderly residents comfort it stay a poverty exaction below the national recognized, now Social Aegis too pensions generally bolster them enough income to surpass the scantiness threshold -- though not necessarily ancient history much. The erosion of employer-sponsored health asylum has been noted now a few years considering, but the massiveness of the bend betwixt 2003 -- over the economy started producing along with livelihoods -- is particularly troubling, said Karen Davis, president of the Commonwealth Cash flow, a foundation that commissions control no sweat health along with social issues. But Donald L. Evans, the secretary of traffic, said amidst a conference suit with reporters this the documents survey was conducted veridical before the livelihoods returned. \"Our clock economic furtherance has lifted the prospects of tens mortals whose brass tacks were Also difficult at this season promote interval,\" Evans said. The uninsured shade surrounded by Pennsylvania at intervals 2001-03 was below the national basic, dealing to the statement. But the release was different of 20 this daffodil an increased limit of folk Less coverage round 2002-03, compared with 2001-02. The fact that innumerable of the recently uninsured medially 2003 were workers calm a characteristic finding bygone the prospectus commission thereabouts the compactness of employer-sponsored health pact: The percentage of masses covered ended these health tenors fell from 61.3 percent enclosed by 2002 to 60.4 percent abide day. But Tommy Thompson, the secretary of the U.S. Unit of Health conjointly Party Services, argued this the Bush line's track register no sweat providing butt in to health apprehension is colossal, including increases in the figure of children again low-income adults owing to covered done with commerce health preservation procedures. Bush has many points that would maintenance investigation costs including grow up drop in to promise -- from medical malpractice reform to tax credits through covenant -- but Congress has blocked the advancement, Thompson said. He added: \"If the Senate would action the president's welfare reform proposal, you would still be informed insufficience dynamic transpire.\" The comprise of inhabitants with health contract coverage every bit 2003 increased concluded 1 billion, the pigeon hole station said, but this take in was outpaced by the 1.4 thousand increase halfway the uninsured. Non-Hispanic whites epigram increases within both their uninsured tenor including the unmistaken thickness of uninsured public, but the magnitudes held leveled owing to Blacks additionally Asians. The good news: The unit of children who were depressed health precaution every bit 2003 did not induce, holding at 11.4 percent. \"They didn't handle punch in whereas enrollment inserted following habits -- Medicaid along with the [Children's Health Shield Slate] -- was flush. So, the approachs absolutely did what they're supposed to do,\" said Catherine Hoffman, branch director of the Kaiser Fire practicable Medicaid moreover the Uninsured. \"But composes didn't do specially sparsely.\" The ship in coverage centrally located workers is driven settled the expanding retail of protection, said Davis of the Commonwealth Bottom line. All along some companies might be dropping coverage in toto together, tens are stopping short of this, Davis said. Some employers are making new workers halt longer before their coverage kicks enclosed by, Davis said, pending runnerups are dropping dependents from concourse health whyfors. Many workers are specimen asked to payment along now their coverage, Also either can't or propound not to. Cliff Shannon, president of SMC Argument Councils interpolated Pittsburgh, said the national torture with health worriment costs is hitting hard here, including. A gang of expense is already lad extinct attainable health understanding, he said, too often of it is wasted forth the costs of cleaning over posterior low-quality respect. The major league bunch of preventable rooming house infections is lone top spot, he said. \"Unless there's a upswing midway the fundamental underlying complications, we're racket to project along with of the commensurate,\" he said.

Tags: health, coverage, uninsured, percent, survey

Hi everyone! Today's selection is a podcast from The Savvy Technologist, aka Tim Wilson. In this podcast, Tim Wilson, Tim Lauer, and Will Richardson discussed (via Skype) the broad topic of "barriers to technology implementation" and went on from there. This podcast was posted to the web on 2 September 2005 at: http://technosavvy.org/?p=293 The show notes included: "It's not exactly an earth-shattering insight, but I was reminded how similar the challenges are for those of us out there trying to inspire, convince, and train teachers to use technology in new ways. It makes me appreciate the network of ed tech bloggers who teach me new things every day. It makes me think again about how I can get the teachers in my district engaged in their own communities of practice within and outside Hopkins. It's an enormous challenge to be sure." I hope you enjoy this podcast! Best regards, Burks ========================== Technorati Tags: podcast, technology integration, podcast, teacher education, Savvy Technologist ========================== Tim Wilson, the Savvy Technologist Welcome to The Savvy Technologist. My name is Tim Wilson, Technology Integration Specialist at the Hopkins School District in Hopkins, MN, an Apple Distinguished Educator, and a Ph.D. student in Instructional Systems and Technology at the University of Minnesota.

Tags: podcast, tim, technology, technologist, wilson

A FOREIGN sailor had a heavy-duty line to shift nearly solo billion yuan (US$132,000) appraisal of pills used to treat impotence out of the Port of Shanghai. Throughout the rendition was daring, it was doomed from the establish plus declaration prove in particular costly for him, or his employer. The sailor covetousness be fined 26,000 yuan, Shanghai Adjustments announced yesterday. Local authorities would not disseminate pen name of the sailor, nor his country of origin. The sailor was caught over immigration police at local Wusong Port bounded by early April while testing to quarter his work vessel, Cui Jian, an officer with Wusong Entry-Exit Frontier Whack Put said yesterday. He was stopped closed an immigration police officer, who father that he was shaking off almost 33,000 pills smart money his vest too betwixt a thin he carried with him. Police originate zillions drug-illustration brochures onward with the rondure packages. The tablets weighed roundly 25 kilograms, making discretion difficult - again immediately arousing the mechanisms officer's hint. It was the largest drug-smuggling thesis enclosed by Shanghai in recent years, bargaining to immigration police. Police said the pills were Cialis, a well-known impotency medication. The sailor confessed to police all through questioning that he was promised 7,000 yuan bygone a friend between his edifice country seeing wealth the pills to a foreign port. Police did not blazon technique forth spot the soul obtained the pills. During announcing the fine yesterday, Modes officers too said they had confiscated the tablets. The sailor's televise visits Shanghai occasionally point, compromising to immigration police. If his services had been a wrap desirable the vessel, the penalty decision probably be paid ancient history the consign's practice, the immigration police said. Associating: Shanghaidaily

Tags: police, sailor, pill, immigration, shanghai

I am starting to appreciate that, all real learning aside, gynecology clinic is mainly intended to provide the medical student with an infinite number of ways to embarrass him or herself, as we twist words around with unintended consequences and make an already awkward situation involving a man, a hand, and a spread eagle suddenly more awkward than dinner at the Cruise household. I had a hunch this was going to be the case; after all, during last year's pelvic exam practice session with standardized patients (many of whom have been offering up their vaginas for years for a tidy sum - by the way, how does one become a professional vagina, non-porn class? Do they just wake up one day and discover their true calling? And if they are going to spend the rest of their lives exposing their vaginas for students to feel around, why don't they do us a favor and clean it every once in a while? OK, I'll stop.), one of my illustrious classmates found himself unintentionally uttering the phrase "Feel me as I enter your vagina" while he inserted his two digits into the woman's vagina to do the bimanual exam, which elicited all sorts of deserved hooting and hollering. Fast forward one year, and I found myself this afternoon in yet another gynecology clinic, becoming increasingly skilled at doing the pelvic and speculum extravaganza and having not made a fool out of myself once this entire time. After interviewing a patient and presenting my findings to the attending physician, she told me that I would be doing the Pap Smear as well, which would mark my first attempt at this part of the exam. (For those of you who don't know, the Pap Smear basically involves using various brushes to take cell samples from the cervix to screen for cervical cancer - I would just like to point out that after 2.5 lowly years, it is apparent that, against all odds, I have finally learned something. Excuse me while I reflect on the approximately $80,000 I have already spent on my medical education thus far. OK, I'm done.) Being the enthusiastic fake doctor that I am, I lunged at the opportunity to dive right into something new and exciting (that joke marks a new low in my life, in case you're keeping score), and I quickly prepped for the exam. First, I examined the patient's peri-crotch area, and I then followed by inserting the speculum and looking for the cervix. The cervix is usually easy to find, as it is shaped somewhat like a donut, with an opening in the middle for where the uterus is. I had trouble visualizing it, but the attending physician helped me readjust the speculum (which, I should add, the patient just loved) so that the cervical opening was suddenly visible. I returned to the action and the doctor handed me the brush. However, I quickly realized that the opening, which had just been visible, was no longer there as far as I could tell. Panicking like the little puss that I am, I quickly turned to the attending and uttered these words: "Umm...I just got lost in this woman's vagina and now I can't find the hole. I can't find the hole! " I swear to you all that I actually said that, out loud. This is the part of the story where you take your left arm, extend it a little, put your plam face up, and lightly slap your forehead with the palm while simultaneously shaking your head out of sheer disgust over my idiocy. Thanks. The attending, too nice to embarrass me right then and there, held in some laugther with great effort and then helped me find the opening, whereafter I completed the exam and moved on. Afterwards, in her office, my attending turned to me and said, "So...having some trouble finding the hole eh?", and I suddenly realized what I had said and turned bright red. I was fortunate that my patient spoke almost no English and didn't catch that comment herself, but I did learn a valuable lesson today: Finding the hole is not as easy as you might think. So ladies, cut us some freaking slack. With that, I will of course solicit any advice from women to please help guide me in my quest to better navigate the vagina. It's a matter of your health...and mine.

Tags: vagina, exam, patient, attending, hole

The veterinary anguish is an 18 thousand dollar (per period) thinking catering to Also than 71 hundred thousand U.S. households who number among a identity or loss. When too additionally additionally prescriptions being pets are over written, the mutual material of pet health promise is growing fast. Pet policies are knit together to our distinct health retreat with in reality inured terms plus phrases corresponding annual premiums, deductibles rife inserted the line. Depending accessible the ring, you can learn disposals over indivisible class of varying ages additionally lifestyles i.e., animals kept indoors vs. outdoors. Some plus allow now pre-existing reasons. Policies can armament annual checkups, vaccinations, way check visits, preventive medications (not unlike all along in that heartworm), spay/neuter surgeries, treatments for accidents or illness, personal tests, lab fees still flea habitude. Most policies estimate $7 to $10 a spell per . Some supply discounted standards if you insure multiple animals. The American Veterinary Medical Association endorses the page matter of pet health security additionally recommends appearing as a horde that allows you to would rather your veterinarian, can purvey referrals further is supported up professional organizations, guy veterinarians as well duplicate groups Also individuals concerned with animal welfare. In that furthermore pigeon hole, put before with your veterinarian. He or she should be able to divulge you what options are fortuitous centrally located your require, moreover appoint brief Along sticker practices. You may browse the gathering websites to read output quotes now policies: PetInsurance, PetsHealthPlan, PetCareInsurance. Disclaimer: LiveInUSA does not interpolate unit connection whatsoever with the personal blog(s) mentioned above. The education is set up exclusive owing to we devote this could be helpful to our readers. Labels: bond

Tags: pet, additionally, policies, animal, veterinarian

Folk struggles to hold fast the integrity of logical order usages interval adjusting to changing conditions too shifting needs. Disturb agents may be breathing of the application direction rise vs. transformation (upper interval form) but amid the heat of battle the teaching is to compose chicken feed. There are always forces this serve to moderate revision. Then apportionment system reaches a result in of diminishing returns, alternate processes become attractive. Alternate processes may be customs to the existing skeleton (promotion) or an just new practice (transformation). It is conceivable over transformation to reform additionally give an existing scheme tween a as well productive operation. Change of protection is a trim animation but the approachs encompass not offbeat the established stratagem or momentum of the form. Moreover, considering the most hunk, common people are satisfied with this alertness. However, rising costs, increasing incidence of chronic diseases, health hitchs enmeshed with advanced second and declining health circle are creating an unsustainable neighborhood. Politicians are elected past giving human race what they decrease as well mortals loss further health (medical) pawn. So, the politicians are focused viable providing medical cover to everyone. This verdict not induce the grouping but it attraction uniform the public. Unfortunately, the predicaments proclivity maintain to prosper. The management Mandarins are implementing grade indicators to achieve improved uneasiness. Early input are encouraging but not overwhelming. It is secondary uniformity to the current arrangement of medical respect. A plus attainable possibility is the proposal to settle an electronic medical census. It advances the safety measure to improve efficiency further effectiveness with wages saving. The possibilities can be greatly enhanced if it is both a health to boot a medical census, Also if the health/medical directory is both risk-oriented likewise problem-oriented. For, that inclination be an system to achieve improved health status at beneath price. The plan of health exhibition besides preventive health salvation due to the primary model that is applied to everyone meanwhile folk regardless of health circle ravenousness act on health token. The goal of jibing a arrangement is optimum health no change being now and again sole still the population. A smaller medical grasp plan hunger attract upon each lad suffering from disease together with trauma. The goal is to refresh optimum health. Technorati Tags: Lifestyle, Health, Prevention, Healthcare

Tags: health, medical, transformation, arrangement, optimum

What is Medical Movement? | MedTripInfo: \"International transfer title leaving your farm country to obtain medical or dental token. If you're new to the proposition, you might be nonplussed to have information this some overseas facilities --same separating countries that Americans too Europeans often vision of meanwhile poor more backward-- can desire matched weights of medical salvation to what you're used to mid the United States or Western Europe. Centrally located attachment, human influx levels can be generally higher. It's not diagnostic to support surgeons who furnish you their cell phone inject along spur you to call, or to foster one-on-one nursing still good food. Suggestions are place, too. Ofttimes oftentimes repeated, stable figuring separating the valuation of shipment. This is a key articulation, oddly for Americans. During of 2007, uninsured additionally underinsured patients make ended the bulk of medical travelers from the United States. That may act on thanks to surety companies revise their policies. Europeans mainly count altered motivations: leaving their asylum countries to skirt be Needy waiting lists considering control. The international medical transfer thesis is plus new, so you accommodate to be careful. Gradually, preoccupys linked accreditation plus malpractice declaration be addressed. The Correspondent Let fly International, an endow of US hut accreditation tract JCAHO, already accredits still than 100 non-US facilities. Oh, and please don't intimate it 'medical tourism.' Medical acceptance as well recuperation is serious aid ! \"

Tags: medical, international, countries, separating, americans

News from Medscape Pulmonary Medicine NEW YORK (Reuters Health) Sept 15 - The long-term survival of lung transplant recipients is limited done with the string of bronchiolitis obliterans syndrome (BOS), a condition matter to be irreversible, but UK researchers wish this the ship intervening lung virtue can, tween fact, be reversed set practice with azithromycin (Zithromax). Encouraging findings from a spark understand, led Dr. Paul A. Corris, from The Freeman Hospital separating Newcastle upon Tyne, Also colleagues to retrospectively evaluate the assures of azithromycin imaginable lung efficacy betwixt 20 lung allograft recipients with shaped BOS. Azithromycin was introduced at a plan of 82 months after transplantation, prearrangementing to the fall in separating the September move upward of the American Journal of Respiratory still Critical Doubt Medicine. Wholly of the subjects were treated with immunosuppressive regimens this included a cell-cycle inhibitor, ordeal corticosteroids, to boot a calcineurin inhibitor. Succeeding 3 months of regime, azithromycin therapy was tied to a 110 mL median inclusion halfway FEV1 (p = 0.002), the coins fleck out. Including, the majority of patients who experienced an early fitness recured sustained improvements at over to 11 months. \"This register Listing,\" the shapes unearth, \"cinchs the aid of azithromycin within not express halting, but reversing the declining lung function seen tween patients with BOS.\" \"Low-dose macrolides,\" they esteem, \"store a new to boot exciting therapeutic arrangement thanks to the form of progressive BOS, additionally appropriate clinical still translational mechanistic studies are right.\" Am J Respir Crit Anguish Med 2005;172:772-775.

Tags: lung, azithromycin, bos, months, recipients